Vena Research Center, Inc

Contract Research Organization providing Services to Ph...


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

Quality Scientific Innovations (QSI)

Vena Research Center, Inc, as a Contract Research Organization (CRO), mission is to provide Quality Scientific Innovations that meet current Scientific trends and requirements in the Pharmaceutical\Biopharmaceutical industry.

Service Details

VRC plans to operate as a Contract Research Organization (CRO) offering the following services to the Pharmaceutical/Biopharmaceutical industry:

• Animal Studies Services
• Analytical Services
• Good Manufacturing Practice (GMP)
• Good Laboratory Practice (GLP)
• Good Clinical Practice (GCP)

Animal Studies Services:

The department will mainly conduct drug safety (Toxicology and Safety Pharmacology) and ADME (Absorption, Distribution, Metabolism and Elimination) studies.  These services include study design, implementation, conducting and monitoring studies, and review of results and conclusions (Reports).

Analytical Services:
Our Analytical services will span from offering biopharmaceutical analytical test platforms to small molecule method development.

We will provide analytical services support to biopharmaceutical/pharmaceutical industry.

Additional services would include:

• Analytical Services to biopharmaceutical/pharmaceutical companies.  In this model we would manage clients Analytical/biopharmaceutical Labs at their facilities using talented Vena Research Center Experts Leaders.
• Vena Research Consulting Services – Would provide additional services to industry offering consultations ranging from our expertise animal toxicity studies to GMP manufacturing compliance.

GMP, GCP & GLP Training Services:

VRC plans to offer VENA Signature training onsite or at client’s site for both USA and international clients in the following areas:

• Good Manufacturing Practice (GMP)
• Good Laboratory Practice (GLP),
• Good Clinical Practice (GCP)
 
The services provide an opportunity to gain additional hands-on experience for our clients. Customized trainings are available. Emphasis is placed on FDA compliance when conducting studies or tests.

Traction & Accomplishments

VRC has put together a team of scientific experts with over 100 years of experience in the Pharmaceutical industry. They have established their own patents in relating to solving Pharma drug issues. They have worked with big Pharmaceutical like Glakso Smith Klime, Wyeth, etc in both research and executive levels. They have overseen large operations regionally and globally to help them understand the needs of Pharma.

How We're Different

VRC is a Contract Research Organization (CRO) providing comprehensive, smart sourcing Pharmaceuti-cal\Biopharmaceutical development solutions to the Pharma-ceutical industry.
1.  VRC is acquiring a State-of-the Art Research Lab that would provide the much needed physical and intellectual resources to any Pharmaceutical client as a One-stop solution Center.
2.  VRC is a custom tailored Pharmaceutical\Biopharmaceutical development solution center that is affordable to Pharmaceutical Start-ups to help them succeed in their pursuit of their dreams. Providing a One-stop-shop for drug development firms would greatly reduce the development time to market for some these critically needed drugs.
3.  VRC is not only a regional CRO company, but a global Service provider with rich diverse global connections within the Pharma industry.VRC is different in that we are one of the few startup companies with such diversified services:

Team

Sylvester Kaunda - President/CEO

Brad based executive expertise in management 


Mr. Kaunda brings over twenty years of top notch management experience to this position. He has brad based executive expertise in management, finance, marketing development and information technology which he gained in his position as president and founder of Vena Technologies, LLC and SK Computer Solutions, Inc.


Kennedy C. Malama - Chief Operating Officer (COO)

He brings twenty two years of experience in academic, pharmaceutical industry spanning R&D and commercial.  


as Chief Operating Officer (COO). He will be responsible for overall technical operation of the company, bringing systems, processes, and people to ensure success of VRC’s research portfolio. He brings twenty two years of experience in academic, pharmaceutical industry spanning R&D and commercial. His industry strength includes pharmaceutical R&D, manufacturing, compliance, global technical leadership, CRO relationship management. The diversity of his experience spans about 85% small molecules and 15% others. In his former position at US Pharmacopeia, as Deputy Director, PQM – he oversaw operations for technical work in over 30 countries which includes working with Country FDAs, CROs and manufacturers.


Martin Ragan - Chief Financial Officer (CFO)

He brings fifty five years of diversified accounting and financial management experience to this position.  


Mr. Ragan brings fifty five years of diversified accounting and financial management experience to this position. He has extensive experience in restructuring and turning around businesses in financial distress and returning them to a solid path of profitability. He also has forty years in mergers and acquisitions and taking companies public. H e also served as Chief Executive Officer (CEO) of a Steel company and currently sits on the Board of Directors of three corporations.


Eustace Uku - General Counsel

Dedicated General Counsel 


Mr. Uku has counseled hundreds of small businesses and startups in organizing their ventures, financing and acquisition of real estate and capital equipment. He has also assisted several public agencies in developing and operating small business financing programs that provide startup and expansion financing, including funding for fixed assets and working capital. He has also assisted hundreds of small and medium sized businesses in performing market feasibility studies, developing business plans and obtaining market access. As an attorney, Mr. Uku has focused on financing transactions, negotiating complex contracts and international trade. Mr. Uku holds a Master’s degree in Business Administration from Long Island University. He also holds a law degree from the University of Lagos and a certificate in law from Duquesne Law School. Mr. Uku is a member of the Bars of the Commonwealth of Pennsylvania and Washington D.C. He is also a Registered Investment Advisor


Dr. Gedion Oenega - Director of Analytical Services

He brings over 20 years of Analytical Services experience in the Pharmaceutical industry.  


He is a subject matter expert, who approaches work with passion, has strong work ethic, and a professional attitude. He successfully developed new robust alternate analytical procedures and methods for 4 products resulting in 50% increase in test throughput. He led technology team in evaluating and recommending a vendor to produce 10 devices worth $10 million for monitoring product quality, resulting in huge cost savings and improved efficiency. He was the recipient of the Performance Incentive Bonus Award in helping the Company achieve its strategic goals


The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service funding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.